SAN FRANCISCO: Study findings indicate no clinically significant effect of avagacestat on cerebrospinal fluid amyloid biomarkers or clinical measures of prodromal Alzheimer’s disease.
“Avagacestat (BMS-708163) is an oral γ-secretase inhibitor designed for the selective inhibition of ß-amyloid (Aß) synthesis relative to processing of Notch substrates. Phase 1 studies demonstrated that avagacestat decreased Aß40 and Aß42 levels at dosages expected to be tolerated in patients. Given that Aß abnormality is an early marker of [Alzheimer’s disease] pathology and seems to change substantially throughout the course of [mild cognitive impairment], avagacestat was advanced into a phase 2 [prodromal Alzheimer’s disease] clinical trial” said…